MA56019A - NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES - Google Patents
NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASESInfo
- Publication number
- MA56019A MA56019A MA056019A MA56019A MA56019A MA 56019 A MA56019 A MA 56019A MA 056019 A MA056019 A MA 056019A MA 56019 A MA56019 A MA 56019A MA 56019 A MA56019 A MA 56019A
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- new compounds
- related pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907616.5A GB201907616D0 (en) | 2019-05-29 | 2019-05-29 | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56019A true MA56019A (en) | 2022-04-06 |
Family
ID=67385363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056019A MA56019A (en) | 2019-05-29 | 2020-05-25 | NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12391679B2 (en) |
| EP (1) | EP3976189B1 (en) |
| JP (1) | JP7550174B2 (en) |
| KR (1) | KR20220015450A (en) |
| CN (1) | CN113924146B (en) |
| AR (1) | AR119028A1 (en) |
| AU (1) | AU2020281650B2 (en) |
| BR (1) | BR112021023900A2 (en) |
| CA (1) | CA3141683A1 (en) |
| CL (1) | CL2021003133A1 (en) |
| CO (1) | CO2021017656A2 (en) |
| CR (1) | CR20210586A (en) |
| DO (1) | DOP2021000227A (en) |
| EA (1) | EA202193281A1 (en) |
| ES (1) | ES2985528T3 (en) |
| GB (1) | GB201907616D0 (en) |
| IL (1) | IL288375B1 (en) |
| MA (1) | MA56019A (en) |
| MX (1) | MX2021013803A (en) |
| PE (1) | PE20220503A1 (en) |
| PH (1) | PH12021552691A1 (en) |
| PL (1) | PL3976189T3 (en) |
| SG (1) | SG11202112652RA (en) |
| TW (1) | TW202110839A (en) |
| WO (1) | WO2020239658A1 (en) |
| ZA (1) | ZA202110597B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| CA3129019A1 (en) | 2019-03-11 | 2020-09-17 | Yong Li | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2022031928A1 (en) * | 2020-08-05 | 2022-02-10 | The General Hospital Corporation | Salt inducible kinase inhibitors |
| USD982434S1 (en) * | 2021-08-31 | 2023-04-04 | Level Up Dice LLC | Dice storage container |
| CN118119619A (en) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | SIK inhibitor and composition, preparation method and application thereof |
| AR128279A1 (en) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES |
| CN115304605B (en) * | 2022-01-21 | 2023-10-03 | 陕西国际商贸学院 | Oxetane derivatives with antitumor activity, and preparation method and application thereof |
| WO2024003209A1 (en) * | 2022-07-01 | 2024-01-04 | F. Hoffmann-La Roche Ag | Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| EP4619397A1 (en) * | 2022-11-17 | 2025-09-24 | Insilico Medicine IP Limited | Salt-inducible kinases (sik) inhibitors and methods of uses thereof |
| WO2024242169A1 (en) * | 2023-05-24 | 2024-11-28 | 田辺三菱製薬株式会社 | Salt-inducible kinase inhibitory compound and pharmaceutical composition containing same |
| CN116813608B (en) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | Thiazole compound and application thereof |
| TW202517630A (en) * | 2023-07-19 | 2025-05-01 | 瑞士商赫孚孟拉羅股份公司 | New benzimidazole pyridine derivatives |
| WO2025068090A1 (en) * | 2023-09-26 | 2025-04-03 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2025232877A1 (en) * | 2024-05-10 | 2025-11-13 | Insilico Medicine Ip Limited | Salt-inducible kinases (sik) inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461162B2 (en) | 2007-07-20 | 2013-06-11 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives |
| JP6261340B2 (en) | 2010-11-18 | 2018-01-17 | リガンド ファーマシューティカルズ インコーポレイテッド | Use of hematopoietic growth factor mimics |
| JP6171149B2 (en) | 2010-12-01 | 2017-08-02 | プレイザン カーボン コンポジティーズ,インコーポレイテッド | Method and system for forming composite articles |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| US10730842B2 (en) | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| CN106496222A (en) | 2016-09-07 | 2017-03-15 | 华东师范大学 | A kind of imidazo [1,2 a] pyridine compounds and its preparation method and application |
| SG11202004925QA (en) | 2017-12-02 | 2020-06-29 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN108358894B (en) * | 2018-04-26 | 2021-05-07 | 四川大学 | Compound for inhibiting histone acetyltransferase as well as preparation method and application thereof |
| CA3103304A1 (en) | 2018-06-15 | 2019-12-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN118684661A (en) | 2023-03-21 | 2024-09-24 | 上海美悦生物科技发展有限公司 | Heteroaryl compounds and pharmaceutical compositions, preparation methods and uses thereof |
-
2019
- 2019-05-29 GB GBGB1907616.5A patent/GB201907616D0/en not_active Ceased
-
2020
- 2020-05-25 WO PCT/EP2020/064368 patent/WO2020239658A1/en not_active Ceased
- 2020-05-25 PE PE2021001955A patent/PE20220503A1/en unknown
- 2020-05-25 JP JP2021570425A patent/JP7550174B2/en active Active
- 2020-05-25 IL IL288375A patent/IL288375B1/en unknown
- 2020-05-25 KR KR1020217042863A patent/KR20220015450A/en active Pending
- 2020-05-25 EA EA202193281A patent/EA202193281A1/en unknown
- 2020-05-25 PH PH1/2021/552691A patent/PH12021552691A1/en unknown
- 2020-05-25 CR CR20210586A patent/CR20210586A/en unknown
- 2020-05-25 MX MX2021013803A patent/MX2021013803A/en unknown
- 2020-05-25 CA CA3141683A patent/CA3141683A1/en active Pending
- 2020-05-25 CN CN202080039185.0A patent/CN113924146B/en active Active
- 2020-05-25 AU AU2020281650A patent/AU2020281650B2/en active Active
- 2020-05-25 SG SG11202112652RA patent/SG11202112652RA/en unknown
- 2020-05-25 PL PL20728465.4T patent/PL3976189T3/en unknown
- 2020-05-25 BR BR112021023900A patent/BR112021023900A2/en unknown
- 2020-05-25 MA MA056019A patent/MA56019A/en unknown
- 2020-05-25 US US17/614,854 patent/US12391679B2/en active Active
- 2020-05-25 ES ES20728465T patent/ES2985528T3/en active Active
- 2020-05-25 EP EP20728465.4A patent/EP3976189B1/en active Active
- 2020-05-28 AR ARP200101505A patent/AR119028A1/en not_active Application Discontinuation
- 2020-05-28 TW TW109117844A patent/TW202110839A/en unknown
-
2021
- 2021-11-03 DO DO2021000227A patent/DOP2021000227A/en unknown
- 2021-11-24 CL CL2021003133A patent/CL2021003133A1/en unknown
- 2021-12-17 ZA ZA2021/10597A patent/ZA202110597B/en unknown
- 2021-12-22 CO CONC2021/0017656A patent/CO2021017656A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112652RA (en) | 2021-12-30 |
| TW202110839A (en) | 2021-03-16 |
| CN113924146B (en) | 2024-12-10 |
| PE20220503A1 (en) | 2022-04-07 |
| JP7550174B2 (en) | 2024-09-12 |
| JP2022534578A (en) | 2022-08-02 |
| DOP2021000227A (en) | 2022-05-15 |
| AU2020281650B2 (en) | 2025-08-28 |
| EP3976189C0 (en) | 2024-07-03 |
| MX2021013803A (en) | 2021-12-14 |
| EP3976189B1 (en) | 2024-07-03 |
| AU2020281650A1 (en) | 2022-02-03 |
| CR20210586A (en) | 2022-01-24 |
| ES2985528T3 (en) | 2024-11-06 |
| WO2020239658A1 (en) | 2020-12-03 |
| PH12021552691A1 (en) | 2022-03-14 |
| PL3976189T3 (en) | 2024-09-09 |
| CA3141683A1 (en) | 2020-12-03 |
| EA202193281A1 (en) | 2022-03-01 |
| CL2021003133A1 (en) | 2022-07-22 |
| IL288375B1 (en) | 2025-09-01 |
| CO2021017656A2 (en) | 2022-01-17 |
| BR112021023900A2 (en) | 2022-01-18 |
| GB201907616D0 (en) | 2019-07-10 |
| US12391679B2 (en) | 2025-08-19 |
| KR20220015450A (en) | 2022-02-08 |
| ZA202110597B (en) | 2024-10-30 |
| EP3976189A1 (en) | 2022-04-06 |
| US20220340548A1 (en) | 2022-10-27 |
| CN113924146A (en) | 2022-01-11 |
| IL288375A (en) | 2022-01-01 |
| AR119028A1 (en) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56019A (en) | NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| MA51200A (en) | NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| MA52873A (en) | NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| MA51739A (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | |
| MA55325A (en) | COMPOUNDS FOR THE TREATMENT OF PD-L1 DISEASES | |
| MA50391A (en) | NEW COMPOUNDS AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | |
| EP3866781A4 (en) | NEW COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| MA52118A (en) | NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | |
| EP3704108A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BLOOD DISORDERS | |
| EP4045036A4 (en) | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1-ASSOCIATED DISEASES | |
| EP3937932A4 (en) | CGAZ INHIBITORS FOR THE TREATMENT OF AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS | |
| EP3890747A4 (en) | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | |
| MA51524A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASE TISSUES | |
| EP3841086A4 (en) | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | |
| EP3661553A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DEPOSITED DISEASES | |
| MA50905A (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | |
| EP3946357A4 (en) | TOPICAL FORMULATIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES | |
| EP3639833A4 (en) | AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO FAT AND / OR INFLAMMATION | |
| EP3328864A4 (en) | COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS | |
| MA53614A (en) | PROTEIN FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| MA55982A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS | |
| EP3936124A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES | |
| EP4209216A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS | |
| EP3919052A4 (en) | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAL DISEASES | |
| EP3960858A4 (en) | SMALL RNA MEDICINE FOR THE PREVENTION AND TREATMENT OF INFLAMMATION RELATED DISEASES AND THEIR COMBINATION |